Navigation Links
Outlook improves for patients with non-Hodgkin lymphoma over past decade
Date:3/10/2008

Five- and 10-year survival rates for patients with non-Hodgkin lymphoma appear to have increased from the 1990s to the early 21st century, according to a report in the March 10 issue of Archives of Internal Medicine, one of the JAMA/Archives journals.

Non-Hodgkin lymphoma includes several cancers of the immune system that occur in approximately 20.4 of every 100,000 individuals, according to background information in the article. Treatment for the condition has evolved rapidly in recent years.

Dianne Pulte, M.D., of the German Cancer Research Center, Heidelberg, and colleagues analyzed data from the Surveillance, Epidemiology and End Results (SEER) Program of the U.S. National Cancer Institute. Survival rates were calculated based on two-year time periods between 1990 and 2004 within which patients were diagnosed with non-Hodgkin lymphoma, as well as by age group (15 to 44, 45 to 54, 55 to 64, 65 to 74 and 75 years or older), sex, race, tumor location (i.e. whether the disease was nodal [in the lymph nodes] or extranodal [in a site other than the lymph nodes]) and histologic subtype (to classify tumors as high-grade or low-grade).

Overall, five-year relative survival increased from 50.4 percent to 66.8 percent, and 10-year relative survival increased from 39.4 percent to 56.3 percent between 1990 to 1992 and 2002 to 2004, the authors write. Improvements were most pronounced in patients younger than 45 years (plus 26.8 and plus 27.1 percentage points for five- and 10-year survival, respectively), but improvements were seen in all age groups, in both sexes, in both nodal and extranodal disease and in both low-grade and high-grade disease. Improvements in prognosis were less in black patients than in white patients, especially in younger black patients.

Two factors may explain these improvements, the authors note. One is advances in therapy that have occurred between 1990 and 2004, particularly the introduction of antibody therapy for non-Hodgkin lymphoma, they write. Treatment with antibody therapy and chemotherapy has extended life expectancy in many cases, but whether and how often this extension represents a true cure is still unknown. In addition, improvements in the treatment of HIV have reduced the occurrence of HIV-related non-Hodgkin lymphomas and also made them easier to treat.

Our estimates of long-term survival in patients with non-Hodgkin lymphoma obtained by the period analysis method for the 2002 to 2004 period are much higher than previously available survival estimates, which mostly pertain to patients diagnosed in the 1990s, the authors conclude. Timely disclosure of the improvements in survival achieved in patients, clinicians, researchers and the public is essential.


'/>"/>

Contact: Hermann Brenner
h.brenner@dkfz-heidelberg.de
JAMA and Archives Journals
Source:Eurekalert

Related medicine news :

1. Gentiva(R) Health Services Announces Fourth Quarter and Fiscal 2007 Results, and Raises 2008 Outlook
2. Legislative and Regulatory Outlook - 2009 and Beyond for Pharma, Biotech Players
3. Beckman Coulters 4th Quarter and Full Year 2007 Revenue Grows 10.8% and 9.2%, Respectively; 2007 Earnings Per Share Beat Outlook
4. Cardinal Health Reports Second Quarter Results, Revises EPS Outlook
5. Matrixx Initiatives, Inc. Updates 2007/2008 Cold Season Trends and Fiscal 2008 Sales and Earnings Outlook
6. Stereotaxis Provides Fourth Quarter 2007 Revenue Outlook
7. Medco CEO Reiterates Guidance, Positive Outlook for 2008
8. Private Equitys Top Execs to Share Advice, Candid Predictions at 2008 Outlook Conference
9. WellPoint Highlights 2007 Accomplishments and Strong 2008 Outlook at Annual Investor Meeting
10. MedCath Corporation Reports Fourth Quarter Earnings and Outlook for Fiscal 2008
11. Dynavax Announces Third Quarter 2007 Financial Results and Updates 2007 Financial Outlook
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/29/2016)... ... 2016 , ... Since launching its annual volunteer campaign on ... footwear industry, has broken all previous participation records in its first two weeks ... during the months of April and May, the 2016 Footwear Cares initiative is ...
(Date:4/29/2016)... , ... April 29, 2016 , ... On Tuesday, April ... across the Southeast, celebrated the signature of Gov. Nathan Deal on SB 258, the ... Duncan (R - Cumming), offers a 70% tax credit to individuals and corporations which ...
(Date:4/29/2016)... ... April 29, 2016 , ... Conditions were ideal for Global Lyme Alliance’s ... Sunday, with sunny skies, a light breeze and temperatures in the 60s. Over 400 ... 5k Run and Walk and 1-mile walk were held to increase awareness about ...
(Date:4/29/2016)... ... April 29, 2016 , ... ... student team BioCellection won the $30,000 Perlman Grand Prize of the 2016 Wharton ... Undergraduate Award, the Michelson People’s Choice Award, and the Committee Award for Most ...
(Date:4/29/2016)... , ... April 29, 2016 , ... Melanoma is the deadliest type of skin cancer. ... for the majority of skin cancer deaths. More than 10,000 people are expected to die ... diagnosis is 62, it is the one of the most commonly diagnosed cancers in young ...
Breaking Medicine News(10 mins):
(Date:4/27/2016)...  Hologic, Inc. (Nasdaq: HOLX ) ... fiscal second quarter ended March 26, 2016.  GAAP ... 41.2%, and non-GAAP diluted EPS of $0.47 increased ... a reported basis, and 6.3% on a constant ... good quarter, highlighted by 14.6% growth in non-GAAP ...
(Date:4/27/2016)... , le 27 Avril 2016 ... d,affaires a progressé de +5% sur le trimestre, ... récurrentes de consommables  Croissance de +16% ... Mauna Kea Technologies (Euronext : MKEA, ... d,endomicroscopie confocale laser, annonce aujourd,hui son chiffre d,affaires ...
(Date:4/27/2016)... -- Elekta today announced that its leading-edge ... focal point of seven scientific presentations at ESTRO 35, ... & Oncology, taking place April 29 - May 3. ... and a high-field MRI scanner with sophisticated software that ... in real time. The MR-linac is designed to improve ...
Breaking Medicine Technology: